Table of Contents
Ready to See Results?
From strategy through execution, Atlantic Health Strategies integrates compliance, operations, and growth into durable, measurable results. Let’s put our expertise to work for your organization.
Answer first: your Medicaid dollars are conditional
If you run a residential SUD facility with more than 16 beds and any share of your revenue comes from Medicaid, your reimbursement depends on your state’s Section 1115 SUD IMD-exclusion waiver. Federal financial participation flows only while the state maintains an ASAM continuum, holds a 30-day statewide average length of stay in residential and inpatient IMD settings, keeps community transitions intact, and demonstrates access to medications for opioid use disorder.
KFF’s 2026 review of state summative evaluations makes the policy backdrop plain. KFF analysts write that “the 2025 Reconciliation Law included historic restrictions in Medicaid financing and coverage that could make it hard to maintain incremental expansions in mental health and SUD benefits.” Operators should reprice risk on every residential asset that leans on IMD-waiver Medicaid.
The exposure is not theoretical. As of April 2026, six states have completed summative evaluations of their SUD IMD waivers: California, Indiana, New Hampshire, Utah, Washington, and Massachusetts. Medicaid is the payer of record for a large piece of this population. KFF reports that Medicaid covers 47% of nonelderly adults with OUD and 56% of those receiving medication for opioid use disorder. If the waiver breaks, the revenue model breaks.
What the waiver actually requires, in operator terms
The framework starts with CMS State Medicaid Director Letter 17-003, which replaced the 2015 guidance and set the milestones states must meet to keep the federal match flowing to IMD residential care. The letter is blunt: “FFP for services in IMDs may be withheld if states are not making adequate progress on meeting the milestones and goals.” Read that twice. CMS can shut off the federal match mid-demonstration.
Two conditions bite hardest at the facility level.
The 30-day statewide length-of-stay average. Under the 2017 guidance, states may claim federal Medicaid matching funds only for short-term stays and must maintain a 30-day statewide average length of stay in inpatient and residential treatment. That average is aggregated across the state, but it is built from your facility’s LOS data.
ASAM continuum fidelity and MOUD access. The 2017 guidance, in KFF’s summary, added more specific demonstration components: residential treatment provider qualifications and capacity, opioid prescribing guidelines, access to naloxone, prescription drug monitoring programs, and care coordination between residential and community settings. If your utilization management team cannot document step-down to outpatient withdrawal management or a lower residential level within a defined window, expect denials and audit exposure.
A note on level naming. Under the ASAM Criteria 4th Edition, residential withdrawal management is Level 3.7. Many state STCs still cite 3rd-edition Roman numeral levels (III.1, III.5, III.7). Do not conflate the two in the same document. If you are not certain of the exact 4th-edition label your state’s STCs reference, describe the clinical model plainly in your monitoring reports. And remember: partial hospitalization (PHP) is an outpatient level of care, not residential. STC crosswalks that muddle that point create audit findings.
State renewal risk is the number buyers keep missing
Waivers are five-year demonstrations. KFF notes that Section 1115 IMD waiver demonstrations typically last five years and require states to meet specified goals, milestones, and evaluation requirements. The KFF waiver tracker is where operators should confirm status for any state where they hold assets.
KFF is careful to call the findings directional, not causal. KFF analysts describe results as “directional signals that contribute to an emerging evidence base on how SUD IMD 1115 waivers may affect access and outcomes.” CMS reviewers read the same caveat. That latitude cuts both ways at renewal.
Here is what operators and PE buyers should price in:
- Renewal timing. If your state’s waiver expires within your hold period, model at least one scenario where CMS conditions renewal on tighter LOS enforcement or narrower LOC coverage. A 15% haircut to residential Medicaid revenue in year three is a defensible base case, not a stress case.
- Corrective action exposure. Per SMD 17-003, CMS may require states to submit corrective action plans if a state fails to meet the required annual triggers indicating that waiver spending is diverging from the expected trajectory under budget neutrality. A state-level corrective action plan becomes a rate or utilization squeeze at the facility level, usually within two quarters.
- Deferral risk. Approved STCs put a hard dollar figure on non-compliance. Missouri’s SUD/SMI STCs state that up to $5,000,000 in FFP for services in IMDs may be deferred if the state is not making adequate progress on meeting the milestones, and the same $5M figure appears verbatim in other approved STCs.
We recently supported a five-facility, three-state accreditation cycle across three levels of care where the operator wanted The Joint Commission stamp before its Medicaid MCO recontracting window. All five earned three-year accreditation on the same survey cycle. Renewal risk is not abstract for those teams. They are building the evidence file now.
The pro forma stress test we run at AHS
Explainer shops will tell you the waiver exists. That does not protect your revenue. Here is the operator-side checklist AHS uses when we pressure-test a residential SUD pro forma or diligence a target for a PE buyer.
- Map every Medicaid dollar to a waiver authority. Is it Section 1115 IMD waiver, SUPPORT Act 1915(l) state plan option, managed care in-lieu-of, or non-IMD state plan? The Congressional Research Service notes that under managed care, states may make payments to MCOs for enrollees aged 21 through 64 who are patients in an IMD as long as the length of stay is no more than 15 days during the month of the payment. Each authority has a different renewal risk profile.
- Pull the facility’s actual ALOS by level of care for the last 8 quarters. Compare against the state’s reported 30-day statewide average from the CMS mid-point assessment. If the facility runs materially above the state’s number, model a payer-driven LOS haircut of 5 to 10 days per admission on residential revenue.
- Score MOUD access on-site. CRS defines an eligible IMD as one that (1) follows reliable, evidence-based practices and (2) offers at least two forms of medication-assisted treatment for SUDs on site. If the target contracts MOUD out without warm-handoff records, that is a diligence flag worth 2 to 4 turns on multiple.
- Test transitions of care. Percent of residential discharges with a documented outpatient appointment within seven days is the metric MCOs are starting to trend. Below 70% and you have a story to tell auditors.
- Model a downside where the waiver renews with tighter STCs. Rerun EBITDA assuming 20% to 30% of Medicaid residential revenue reverts to the SUPPORT Act 30-day-or-less cap. Assume a per-admission net revenue drop in the range of $3,000 to $6,000 on stays that used to run 45 days and now run 30. That is your realistic worst case, not zero.
What to put in front of your board this quarter
Three items belong on the board deck before the next CMS mid-point assessment lands.
One. A state-by-state matrix. Map every facility to its Medicaid revenue mix, its waiver authority, and the expiration date pulled directly from Medicaid.gov. Colorado’s SUD Continuum of Care waiver, for example, was approved effective January 1, 2021 through December 31, 2025, which means any Colorado operator is in an active renewal window right now. Read your own state’s STCs the same way.
Two. A short memo on federal exposure. KFF published its SUD IMD waiver evaluations against the backdrop of the 2025 Reconciliation Law, which KFF flags as containing historic Medicaid restrictions that may constrain SUD benefit expansions. Any pro forma that carries residential Medicaid revenue at flat rates for the next five years is out of step with what Congress signaled in that legislation.
Three. A documentation plan. CMS reviewers use the word “directional” for a reason. Operators who keep their revenue at renewal are the ones who built the evidence file quarter by quarter. Not the ones scrambling in the 90 days before submission.
Colorado, Missouri, Florida, Virginia, Nevada. Pick your state, then read the STCs. The specific expiration date and the specific milestone language are what belong in the board deck. Not a generic summary of the program.
Frequently asked questions
Which states currently have approved Section 1115 SUD IMD-exclusion waivers?
Per KFF’s April 2026 review, six states have completed summative evaluations of their SUD IMD waivers: California, Indiana, New Hampshire, Utah, Washington, and Massachusetts. Approved SUD IMD waivers exist in a much larger set of states; the current list is maintained on the KFF Medicaid Waiver Tracker and on Medicaid.gov. Demonstrations typically run five years, so pull the specific end date from Medicaid.gov for any state where you operate or are diligencing an asset.
How does the CMS 30-day statewide average length-of-stay requirement affect residential SUD program design?
The 30-day average is a state-level metric, but state Medicaid agencies enforce it downstream through prior auth, concurrent review, and rate structure. Programs designed around 45- to 60-day stays should expect utilization management pressure, denial risk on continued stays without acuity documentation, and pressure from MCOs to move patients to lower levels of care faster. Every 10 days of denied continued stay at a $650 per diem is $6,500 in lost net revenue per admission.
What happens to Medicaid revenue if a state’s SUD IMD waiver is not renewed or is restricted?
Federal financial participation for residential services in IMDs narrows or stops. Under CRS, the SUPPORT Act managed care in-lieu-of authority caps IMD stays at no more than 15 days during the month of payment, and the 1915(l) state plan option is likewise limited to short-term stays with a maintenance-of-effort requirement. Both are meaningfully more restrictive than most current 1115 waiver terms, so operators should model the 30-day-or-less scenario as their downside case. Approved STCs (Missouri’s, for example) allow CMS to defer up to $5 million in FFP if a state falls behind on milestones.
What ASAM level-of-care documentation does CMS expect residential SUD providers to maintain under a waiver?
CMS expects the state, and by extension its participating providers, to document coverage across the full ASAM continuum, including outpatient, intensive outpatient, partial hospitalization (an outpatient level), clinically managed and medically monitored residential, and residential withdrawal management. Under the ASAM Criteria 4th Edition, residential withdrawal management is Level 3.7. Facilities should produce assessment notes tied to a specific level, provider qualifications by level, and step-down documentation aligned with the state’s STCs.
References
- KFF: A Look at 1115 Waiver Evaluations for Medicaid Payments to IMDs for SUD (2026)
- CMS State Medicaid Director Letter 17-003: Strategies to Address the Opioid Epidemic
- CMS State Medicaid Director Letter 18-011: SMI/SED Demonstration Opportunity
- Congressional Research Service: Medicaid’s Institution for Mental Diseases (IMD) Exclusion
- KFF: Implications of Potential Federal Medicaid Reductions for Addressing the Opioid Epidemic
- KFF Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State
- Missouri SUD/SMI Section 1115 Demonstration Approval and STCs (CMS, December 2023)
- Colorado HCPF: Expanding the SUD Continuum of Care 1115 Waiver